首页> 美国卫生研究院文献>other >Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations
【2h】

Research and Development of Hepatitis B Drugs: An Analysis Based on Technology Flows Measured by Patent Citations

机译:乙肝药物的研究与开发:基于专利引用量测技术流的分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the existence of available therapies, the Hepatitis B virus infection continues to be one of the most serious threats to human health, especially in developing countries such as China and India. To shed light on the improvement of current therapies and development of novel anti-HBV drugs, we thoroughly investigated 212 US patents of anti-HBV drugs and analyzed the technology flow in research and development of anti-HBV drugs based on data from IMS LifeCycle databases. Moreover, utilizing the patent citation method, which is an effective indicator of technology flow, we constructed patent citation network models and performed network analysis in order to reveal the features of different technology clusters. As a result, we identified the stagnant status of anti-HBV drug development and pointed the way for development of domestic pharmaceuticals in developing countries. We also discussed about therapeutic vaccines as the potential next generation therapy for HBV infection. Lastly, we depicted the cooperation between entities and found that novel forms of cooperation added diversity to the conventional form of cooperation within the pharmaceutical industry. In summary, our study provides inspiring insights for investors, policy makers, researchers, and other readers interested in anti-HBV drug development.
机译:尽管存在可用的疗法,但乙肝病毒感染仍然是对人类健康的最严重威胁之一,特别是在中国和印度等发展中国家。为了阐明当前疗法的改进和新型抗HBV药物的开发,我们根据IMS LifeCycle数据库的数据,彻底研究了212项美国抗HBV专利,并分析了抗HBV药物研发的技术流程。 。此外,利用专利引用方法(一种有效的技术指标),我们构建了专利引用网络模型并进行了网络分析,以揭示不同技术集群的特征。结果,我们确定了抗HBV药物开发的停滞状态,并为发展中国家国产药物的开发指明了道路。我们还讨论了治疗性疫苗作为潜在的下一代HBV感染疗法。最后,我们描绘了实体之间的合作,并发现新颖的合作形式为制药行业的传统合作形式增加了多样性。总而言之,我们的研究为投资者,决策者,研究人员和其他对抗HBV药物开发感兴趣的读者提供了启发性的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号